Scinai Immunotherapeutics into binding option agreement to acquire Pincell srl
Scinai Immunotherapeutics enters into a binding option agreement to acquire Pincell srl, focusing on PC111, a monoclonal antibody therapeutic for the treatment of severe skin diseases. An application for a €12 million grant is filed, with a decision expected in mid-July/early August 2025.
Scinai Immunotherapeutics into binding option agreement to acquire Pincell srl Read More »